Combination medications were administered to patients with documented or suspected bacterial co-infections (e.g. pneumonia, sepsis) based on clinical symptoms, laboratory markers (e.g. elevated CRP, leukocytosis), or imaging findings. The gene discussed is CRP; the disease is susceptibility to pneumonia measurement.